Tempus AI Stock Price, News & Analysis

Tempus AI, Inc. (NASDAQ: TEM) is a technology company in the healthcare sector that focuses on health information services and precision medicine. According to its public disclosures and press releases, Tempus advances precision medicine through the practical application of artificial intelligence in healthcare. The company emphasizes using one of the world’s largest libraries of multimodal data, together with an operating system that makes that data accessible and useful for clinical and research purposes.

Tempus has built the Tempus Platform, which includes a technology platform designed to free healthcare data from silos and an operating system that helps make the resulting data useful. The company states that it provides AI-enabled precision medicine solutions to physicians so they can deliver more personalized patient care. In parallel, Tempus facilitates the discovery, development, and delivery of therapeutics by enabling life sciences organizations to work with its multimodal datasets and analytical tools.

Within diagnostics, Tempus highlights its use of artificial intelligence, including generative AI, in Intelligent Diagnostics to make laboratory tests more accurate, tailored, and personal. In oncology and hereditary disease testing, Tempus offers genomic testing capabilities referenced in its collaborations, such as solid tissue DNA and RNA profiling, liquid biopsy, and minimal residual disease (MRD) testing. These offerings are intended to deepen understanding of disease biology and support more individualized treatment decisions.

Role in precision oncology and research

Tempus plays a visible role in precision oncology through collaborations with major academic medical centers and health systems. For example, Tempus and NYU Langone Health announced a multi-year strategic collaboration to support NYU Langone Health’s Center for Molecular Oncology at the Perlmutter Cancer Center. This collaboration focuses on advanced molecular profiling, longitudinal sequencing of patients throughout their treatment journey, and the development and validation of assays and algorithmic diagnostics, including AI-powered predictive algorithms.

Tempus also collaborates with Northwestern Medicine to expand access to genomic testing for cancer patients across cancer types, including those with early-stage diagnoses. As part of that collaboration, Tempus provides genomic testing such as solid tissue DNA and RNA profiling, liquid biopsy, and MRD testing. These partnerships reflect Tempus’s focus on integrating advanced genomic technologies, data science, and real-world clinical data to inform targeted therapies and clinical trial design.

Beyond individual collaborations, Tempus is active in oncology research through its participation in major scientific meetings. The company regularly presents abstracts at conferences such as the ASCO Gastrointestinal Cancers Symposium, the San Antonio Breast Cancer Symposium, and the Society for Immunotherapy of Cancer Annual Meeting. These presentations draw on Tempus’s de-identified multimodal database and tools such as Tempus Lens to analyze genomic, transcriptomic, and clinical data across a wide range of tumor types, biomarkers, and treatment settings.

Data, applications, and life sciences partnerships

Tempus reports that its business includes a Data and applications component, sometimes referred to as Insights or data licensing, which enables biopharmaceutical and research partners to use its multimodal datasets in drug discovery and development. The company has disclosed that it signs data agreements with large and mid-sized pharmaceutical companies and biotechs, which use Tempus’s unique datasets to support their research and development efforts.

The company’s multimodal data library combines de-identified clinical information with molecular data, including genomic and transcriptomic profiles. Tempus uses this resource to develop algorithms, biomarker analyses, and multi-omic models that can help characterize tumors, understand immune microenvironments, and explore treatment outcomes. Its research abstracts describe applications such as Immune Profile Scores, multi-omic target characterization frameworks, and analyses of tumor mutational burden, receptor tyrosine kinase amplifications, and other molecular features.

Financial reporting and capital markets presence

Tempus AI, Inc. is incorporated in Nevada and its Class A common stock trades on The Nasdaq Stock Market LLC under the symbol TEM, as disclosed in its SEC filings. The company provides periodic financial updates through press releases and Form 8-K filings, including preliminary revenue figures and segment performance for its Diagnostics and Data and applications businesses. These communications describe revenue growth, contract values, and net revenue retention metrics, though Tempus emphasizes that certain figures may be preliminary and unaudited when first announced.

Tempus also participates in capital markets activities. For example, the company has disclosed an automatic shelf registration statement on Form S-3 and a prospectus supplement related to the resale of shares of its Class A common stock by selling stockholders. In addition, Tempus completed a private offering of convertible senior notes due 2030, documented in an 8-K filing that describes the notes’ terms, conversion features, redemption provisions, and related capped call transactions. These filings provide insight into Tempus’s financing strategy and capital structure.

Scientific and clinical focus areas

Tempus’s research footprint, as reflected in its abstracts and collaborations, spans multiple cancer types and scientific questions. The company’s work includes genomic profiling of gastrointestinal cancers, pancreatic cancers, biliary tract cancers, neuroendocrine tumors, and breast cancers, among others. It leverages its multimodal database and Tempus Lens to study tumor genomics, transcriptomics, tumor immune microenvironments, and real-world clinical outcomes.

Examples from Tempus’s scientific presentations include studies of KRAS and other gene alterations in appendiceal neoplasms and pancreatic adenocarcinoma, transcriptomic signatures associated with treatment response, and analyses of tumor mutational burden thresholds in relation to immune checkpoint inhibitor outcomes. In breast cancer, Tempus has reported on multimodal models for risk stratification, molecular and immune landscapes across mutation subgroups, treatment sequencing, and real-world outcomes associated with specific biomarkers such as ESR1 and PIK3CA mutations.

In immuno-oncology, Tempus has described algorithms such as the Immune Profile Score, which integrates DNA and RNA-based features to stratify outcomes for patients treated with immune checkpoint inhibitors, including those with microsatellite stable colorectal cancer and rare advanced solid tumors. The company has also presented work on MAIT cell abundance in tumors, androgen receptor alterations in castration-resistant prostate cancer, and multi-omic frameworks for target characterization in immunotherapy and targeted therapy development.

Collaborations with foundations and nonprofit organizations

Tempus’s activities extend beyond academic and industry partners to include nonprofit foundations. The company announced a multi-year research study with the Institute for Follicular Lymphoma Innovation (IFLI), a global nonprofit focused on follicular lymphoma. This study aims to enroll follicular lymphoma patients and generate a comprehensive, multi-omic dataset using technologies such as next generation sequencing, proteomics, and methylation analysis. The collaboration builds on an existing effort to create a consolidated real-world data library for follicular lymphoma and is intended to support biomarker discovery and the development of more personalized therapies.

Through such collaborations, Tempus positions its molecular profiling capabilities and data science infrastructure as tools to help partners better understand disease biology, identify biomarkers, and explore new therapeutic strategies. The company’s stated goal is for each patient to benefit from the treatment of others who came before, by providing physicians and researchers with tools that learn as more data is gathered.

Use of artificial intelligence and multimodal data

Artificial intelligence is central to Tempus’s approach. The company describes itself as a leader in the adoption of AI to advance precision medicine and notes that it uses AI, including generative AI, in its Intelligent Diagnostics. Its operating system and analytical tools are designed to work with multimodal data, combining clinical records, genomic and transcriptomic profiles, and other molecular data types. This integrated approach underpins many of the company’s research outputs, such as multi-omic immune scores, target characterization frameworks, and biomarker analyses.

By integrating AI with multimodal data, Tempus seeks to generate actionable insights about cancer response, resistance, and disease trajectory. Its research abstracts highlight how de-identified clinical and molecular data can be used to characterize tumors, identify new biomarkers, and define tumor microenvironments across large patient cohorts. These capabilities are used both to support clinical decision-making tools for physicians and to inform life sciences partners engaged in drug discovery and development.

Regulatory filings and corporate governance

Tempus’s SEC filings provide additional context on its regulatory and corporate framework. The company files Form 8-K reports to disclose material events such as financial results, credit agreement amendments, securities offerings, and other significant corporate actions. For example, Tempus has reported amendments to its credit agreement, including provisions related to capital raise requirements, and has described events of default and covenants associated with its convertible notes.

These filings also confirm Tempus’s jurisdiction of incorporation, its registered securities, and the exchange on which its Class A common stock is listed. They outline how certain information, such as earnings press releases and supplemental financial materials, is furnished rather than filed for purposes of the Securities Exchange Act of 1934, and they reference the availability of additional materials through the company’s investor relations channels.

Summary

In summary, Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence to precision medicine, with a particular emphasis on oncology. It operates a platform that combines a large multimodal data library with an operating system and AI-driven tools, enabling genomic diagnostics, Intelligent Diagnostics, and data-driven research. Through collaborations with health systems, academic centers, pharmaceutical companies, and nonprofit foundations, Tempus supports personalized patient care and the discovery, development, and delivery of therapeutics, while maintaining a presence in public equity and debt markets through its Nasdaq-listed Class A common stock and disclosed financing activities.